Compare ARDC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDC | HELP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.3M | 281.4M |
| IPO Year | 2011 | N/A |
| Metric | ARDC | HELP |
|---|---|---|
| Price | $12.26 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 114.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.52 | $5.15 |
| 52 Week High | $15.03 | $8.55 |
| Indicator | ARDC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 22.57 | 36.91 |
| Support Level | N/A | N/A |
| Resistance Level | $13.49 | $7.28 |
| Average True Range (ATR) | 0.16 | 0.64 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 15.05 | 0.92 |
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.